These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 6494241)
1. Phase-IV research: specifics, objectives and methodology. Linden M Pharmacopsychiatry; 1984 Sep; 17(5):140-2. PubMed ID: 6494241 [TBL] [Abstract][Full Text] [Related]
2. The private practice study group as phase-IV research tool. Helmchen H; Linden M; Schüssler G Pharmacopsychiatry; 1984 Sep; 17(5):157-61. PubMed ID: 6494245 [TBL] [Abstract][Full Text] [Related]
3. Designs for efficient clinical trials. Simon R Oncology (Williston Park); 1989 Jul; 3(7):43-9; discussion 51-3. PubMed ID: 2701811 [TBL] [Abstract][Full Text] [Related]
5. A 25-year review of sequential methodology in clinical studies. Todd S Stat Med; 2007 Jan; 26(2):237-52. PubMed ID: 17139691 [TBL] [Abstract][Full Text] [Related]
6. Differences in adverse drug reactions in phase III and phase IV of the drug evaluation process. Linden M Psychopharmacol Bull; 1993; 29(1):51-6. PubMed ID: 8378512 [TBL] [Abstract][Full Text] [Related]
7. Strategies for designing clinical trials for oligonucleotide therapeutics. Wacheck V Drug Discov Today; 2004 Nov; 9(21):918-23. PubMed ID: 15501726 [TBL] [Abstract][Full Text] [Related]
8. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846 [TBL] [Abstract][Full Text] [Related]
9. Alternative strategies in drug development: clinical pharmacological aspects. Kuhlmann J Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949 [TBL] [Abstract][Full Text] [Related]
10. Clinical trial design in metastatic breast cancer: a commentary. Levine M Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523 [TBL] [Abstract][Full Text] [Related]
11. Procedures and methods of benefit assessments for medicines in Germany. Bekkering GE; Kleijnen J Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905 [TBL] [Abstract][Full Text] [Related]
12. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems. Glasser SP; Salas M; Delzell E J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697 [TBL] [Abstract][Full Text] [Related]
13. Drug research: from the idea to the product. Kuhlmann J Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711 [TBL] [Abstract][Full Text] [Related]
14. Biostatistics in clinical trials: Part 2. Determining sample sizes for clinical trials. Ellenberg SS Oncology (Williston Park); 1989 Aug; 3(8):39-46; discussion 48, 51. PubMed ID: 2519197 [TBL] [Abstract][Full Text] [Related]
15. A composite design for transition from a preliminary to a full-scale study. Lachin JM; Younes N Stat Med; 2007 Nov; 26(27):5014-32. PubMed ID: 17577245 [TBL] [Abstract][Full Text] [Related]
16. From translational research to a large randomized clinical trial: a long and streanuous way from bench to bedside. Sakamoto J; Morita S Nagoya J Med Sci; 2007 Jan; 69(1-2):9-16. PubMed ID: 17378175 [TBL] [Abstract][Full Text] [Related]
18. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group. Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005 [TBL] [Abstract][Full Text] [Related]
20. Scientific and ethical considerations in trial design for investigational agents for the treatment of human immunodeficiency virus infection. Feinberg J; Japour AJ Clin Infect Dis; 2003 Jan; 36(2):201-6. PubMed ID: 12522753 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]